Skip to main content
NRXP
NASDAQ Life Sciences

FDA 对 NRx Pharma 无防腐剂酮胺给予了积极反馈，目标是2026年夏季获得批准

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
9
Price
$2.95
Mkt Cap
$97.55M
52W Low
$1.62
52W High
$3.84
Market data snapshot near publication time

summarizeSummary

NRx Pharmaceuticals 宣布，其无防腐剂酮胺计划获得了 FDA_Generic Drugs 办公室的积极反馈，包括一份纪律审查信，只要求进行少量行政变更。这一重大监管进展是在三月份获得有利的生物等效性确定之后，并建立在最近总统行政命令的基础上，旨在加速精神病学治疗。对于最近在其 10-K 中报告“继续经营警告”的公司来说，这一积极发展至关重要。FDA 领导层认识到酮胺的国家优先事项，并表示支持在当前审查周期内解决 ANDA 申请的剩余方面，目标是在 2026 年夏季获得批准。这大大降低了关键产品候选者的风险，并为股票提供了明确的、近期的催化剂。交易者将密切监视 ANDA 流程和预期 2026 年夏季批准的进一步更新。

在该公告发布时，NRXP的交易价格为$2.95，交易所为NASDAQ，所属行业为Life Sciences，市值约为$9755万。 52周交易区间为$1.62至$3.84。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed NRXP - Latest Insights

NRXP
Apr 22, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
FDA Gives Positive Feedback on NRx Pharma's Preservative-Free Ketamine, Targets Summer 2026 Approval
Sentiment: Positive
View Wiseek Article
NRXP
Apr 20, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Presidential Order to Fast-Track Psychedelic Drug Approvals Directly Benefits NRx Pharmaceuticals
Sentiment: Positive
View Wiseek Article
NRXP
Apr 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
NRx Pharma's Preservative-Free Ketamine Nears FDA Approval with Minor Labeling Feedback
Sentiment: Positive
View Wiseek Article
NRXP
Mar 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Hope Therapeutics, NRXP Subsidiary, Partners with Emobot to Deploy AI-Powered Depression Monitoring
Sentiment: Positive
View Wiseek Article
NRXP
Mar 24, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
7
Stockholders Approve Significant Increase in Annual Incentive Plan Share Reserve
Sentiment: Negative
View Wiseek Article
NRXP
Mar 23, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
8
NRX Pharmaceuticals Reports Going Concern, Massive Dilution, and Key Regulatory Progress in Annual 10-K
Sentiment: Negative
View Wiseek Article
NRXP
Mar 16, 2026, 7:36 AM EDT
Source: Reuters
Importance Score:
9
FDA Confirms Clear, Accelerated NDA Path for NRX-100 by June 2026, No New Trials Required
Sentiment: Positive
View Wiseek Article
NRXP
Feb 23, 2026, 5:00 PM EST
Filing Type: DEF 14A
Importance Score:
8
NRX Pharmaceuticals Seeks Shareholder Approval for Substantial Increase in Equity Incentive Plan Share Reserve
Sentiment: Negative
View Wiseek Article
NRXP
Feb 17, 2026, 9:21 AM EST
Filing Type: 8-K
Importance Score:
9
NRX Pharmaceuticals Secures Clear FDA Path for Full NDA Approval of NRX-100 with Broader Indication
Sentiment: Positive
View Wiseek Article
NRXP
Feb 17, 2026, 9:20 AM EST
Filing Type: 424B5
Importance Score:
9
NRX Pharmaceuticals Announces Highly Dilutive $20M At-The-Market Equity Offering
Sentiment: Negative
View Wiseek Article